Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty

Cardiovascular Institute, El Camino Hospital, Mountain View, California, USA.

OBJECTIVES. The purpose of this study was to examine the incidence and implications of recurrent ischemia after different reperfusion strategies in acute myocardial infarction. BACKGROUND. The rates and effects of recurrent ischemia after reperfusion with thrombolytic therapy and with primary percutaneous transluminal coronary angioplasty have not been compared. METHODS. At 12 centers 395 patients presenting within 12 h of the onset of acute myocardial infarction were prospectively randomized to receive recombinant tissue-type plasminogen activator (rt-PA) or primary coronary angioplasty. Sixteen clinical variables were examined by using univariate and multiple logistic regression analysis to identify the predictors of recurrent ischemia. The relation of recurrent ischemic events to patient outcome was analyzed. RESULTS. Recurrent ischemia developed in 76 patients (19.2%) before hospital discharge, resulting in reinfarction in 18 patients (4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 patients (28.0%) after rt-PA but in only 20 patients (10.3%) after coronary angioplasty (p < 0.0001), directly contributing to a higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), catheterization and revascularization procedures and prolonged hospital stay after thrombolysis. By multivariate analysis, treatment with coronary angioplasty rather than rt-PA was the strongest predictor of freedom from recurrent ischemia. Although the incidence of recurrent ischemia after angioplasty and after rt-PA was similar within the 1st 2 days of admission (9.2% vs. 14.5%, p = 0.11), after hospital day 2 recurrent ischemia occurred in only 2 patients who received primary angioplasty compared with 27 patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001). CONCLUSIONS. The development of recurrent ischemia adversely affects patient outcome, increasing morbidity, mortality and resource utilization. The much lower rate of recurrent ischemia after primary coronary angioplasty than after rt-PA results in improved survival without reinfarction and allows a shorter, less complicated hospital stay. Given the extremely low rate of recurrent ischemia after hospital day 2, safe early discharge on day 3 after primary coronary angioplasty should be feasible in selected patients with acute myocardial infarction.

This article has been cited by other articles:

				G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention Circulation, July 29, 2008; 118(5): 538 - 551. [Full Text] [PDF]

				M. R. Le May, G. A. Wells, M. Labinaz, R. F. Davies, M. Turek, D. Leddy, J. Maloney, T. McKibbin, B. Quinn, R. S. Beanlands, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study) J. Am. Coll. Cardiol., August 2, 2005; 46(3): 417 - 424. [Abstract] [Full Text] [PDF]

				E. Nikolsky, E. D. Aymong, A. Halkin, C. L. Grines, D. A. Cox, E. Garcia, R. Mehran, J. E. Tcheng, J. J. Griffin, G. Guagliumi, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial J. Am. Coll. Cardiol., August 4, 2004; 44(3): 547 - 553. [Abstract] [Full Text] [PDF]

				D. J. Cohen, D. A. Taira, R. Berezin, D. A. Cox, M.-C. Morice, G. W. Stone, and C. L. Grines Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial Circulation, December 18, 2001; 104(25): 3039 - 3045. [Abstract] [Full Text] [PDF]

				W. J. Rogers, J. G. Canto, C. T. Lambrew, A. J. Tiefenbrunn, B. Kinkaid, D. A. Shoultz, P. D. Frederick, N. Every, and for the Investigators in the National Registry of Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3 J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2056 - 2063. [Abstract] [Full Text] [PDF]

				L. Maillard, M. Hamon, K. Khalife, P. G. Steg, F. Beygui, J.-L. Guermonprez, C. M. Spaulding, J.-M. Boulenc, J. Lipiecki, A. Lafont, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1729 - 1736. [Abstract] [Full Text] [PDF]

				D. Hasdai, C. B. Granger, S. S. Srivatsa, D. A. Criger, S. G. Ellis, R. M. Califf, E. J. Topol, and D. R. Holmes Jr. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1502 - 1512. [Abstract] [Full Text] [PDF]

				P. W. Armstrong, Y. Fu, W.-C. Chang, E. J. Topol, C. B. Granger, A. Betriu, F. Van de Werf, K. L. Lee, R. M. Califf, and f. t. G.-I. Investigators Acute Coronary Syndromes in the GUSTO-IIb Trial : Prognostic Insights and Impact of Recurrent Ischemia Circulation, November 3, 1998; 98(18): 1860 - 1868. [Abstract] [Full Text] [PDF]

				P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial J. Am. Coll. Cardiol., September 1, 1998; 32(3): 620 - 628. [Abstract] [Full Text] [PDF]

				R. W. Smalling and H. V. Anderson Pathophysiological Insight Into the Possible Optimal Therapies for Acute Myocardial Infarction and Unstable Angina Circulation, January 13, 1998; 97(1): 10 - 11. [Full Text] [PDF]

				W. D. Weaver, R. J. Simes, A. Betriu, C. L. Grines, F. Zijlstra, E. Garcia, L. Grinfeld, R. J. Gibbons, E. E. Ribeiro, M. A. DeWood, et al. Comparison of Primary Coronary Angioplasty and Intravenous Thrombolytic Therapy for Acute Myocardial Infarction: A Quantitative Review JAMA, December 17, 1997; 278(23): 2093 - 2098. [Abstract] [PDF]

				J. Hung, M. Moshiri, G. N Groom, A. A Van der Schaaf, R. W Parsons, and M. E Hands Dipyridamole thallium-201 scintigraphy for early risk stratification of patients after uncomplicated myocardial infarction Heart, October 1, 1997; 78(4): 346 - 352. [Abstract] [Full Text] [PDF]

				U. Rosenschein, A. Roth, T. Rassin, S. Basan, S. Laniado, and H. I. Miller Analysis of Coronary Ultrasound Thrombolysis Endpoints in Acute Myocardial Infarction (ACUTE Trial) : Results of the Feasibility Phase Circulation, March 18, 1997; 95(6): 1411 - 1416. [Abstract] [Full Text]

				A. H. B. Wu and J. M. Clive Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain Clin. Chem., February 1, 1997; 43(2): 326 - 332. [Abstract] [Full Text] [PDF]

				J. S. Forrester New Standard for Success of Thrombolytic Therapy : An Earnest Proposal Circulation, October 15, 1995; 92(8): 2026 - 2028. [Full Text]

				PTCA vs. t-PA for Acute MI: Fewer Ischemic Events with PTCA Journal Watch Cardiology, September 1, 1995; 1995(901): 17 - 17. [Full Text]

				PTCA VS. T-PA FOR ACUTE MI: FEWER ISCHEMIC EVENTS WITH PTCA Journal Watch (General), July 18, 1995; 1995(718): 2 - 2. [Full Text]